The Audit That Changes Everything
Most organizations that consume drug pricing data never question it. The numbers arrive from CMS, from pricing compendia, from analytics ...
The Biosimilar Discount Paradox
The promise of biosimilars was straightforward enough to fit on a campaign banner: near-identical versions of expensive biologic drugs, at ...
The Number Nobody Publishes
Ask a pharmaceutical executive what their drug costs, and the answer you receive will depend on what the executive wants ...
The Infrastructure Nobody Built
There exists no public system that maps a drug's price across WAC, NADAC, and ASP in a unified, unit-normalized, continuously ...
Which Price Is the Real Price?
An analyst covering a mid-cap pharmaceutical company sits down with the latest quarterly filing and encounters a familiar problem. The ...
Transparency Without Translation
The premise seemed elegant: require pharmaceutical manufacturers to disclose the data behind drug price increases, and the resulting transparency would ...
The Rebate That Ate the List Price
Every quarter, pharmaceutical manufacturers who want their drugs covered by Medicaid submit a number to CMS that determines how much ...
The Specialty Pharmacy Blind Spot
The drugs that cost the most are the drugs we know the least about — at least when it comes ...
Ain’t What’s Paid — And Never Was
A pricing benchmark that the industry itself nicknamed "Ain't What's Paid" would seem unlikely to survive the reputational damage. Average ...
The Gross-to-Net Bubble
There is a number that pharmaceutical executives discuss constantly in private and reference obliquely in public. It is not a ...
The Dosing Assumptions Hiding in Plain Sight
Comparing the cost of two drugs that treat the same condition sounds like a straightforward exercise. It is not. Drug ...
The Gold Standard That Comes with Caveats
If you have read an academic paper, policy brief, or investor report that estimates a drug's net price in the ...
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more